Poxel S.A. | Balance Sheet

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
7,971.40
10,253.60
42,413.40
45,568.60
54,163.50
66,737
Total Accounts Receivable
4,143.10
3,210.00
2,544.00
3,881.00
11,536.80
20,452
Inventories
1.20
2.80
0.20
0.60
-
-
Other Current Assets
120.80
51.70
1,203.80
151.00
552.30
1,081
Total Current Assets
12,236.50
13,518.10
46,161.40
49,601.20
66,252.50
88,270
Net Property, Plant & Equipment
20.60
21.30
152.70
145.40
143.30
296
Total Investments and Advances
8.60
285.60
533.40
310.40
67.40
93
Intangible Assets
0.10
0.90
0.50
0.50
0.50
16,578
Other Assets
-
-
-
120.30
159.10
201
Total Assets
12,265.80
13,825.90
46,848.10
50,177.70
66,622.90
105,438
ST Debt & Current Portion LT Debt
26,646.80
8,551.30
2,366.10
1,009.20
935.80
Accounts Payable
4,479.20
3,098.70
2,824.50
4,915.70
3,249.30
Income Tax Payable
72.00
60.00
59.90
49.40
44.20
Other Current Liabilities
265.80
247.90
1,885.90
4,104.20
42,411.20
Total Current Liabilities
31,463.80
11,957.90
7,136.40
10,078.50
46,640.50
Long-Term Debt
726.90
3,865.80
1,553.90
708.60
555.20
Provision for Risks & Charges
85.30
97.80
130.00
131.20
229.90
Other Liabilities
-
451.90
-
-
-
Total Liabilities
32,276.00
16,373.40
8,820.30
10,918.30
47,425.60
Common Equity (Total)
20,010.20
2,547.50
38,027.80
39,259.40
19,197.30
Total Shareholders' Equity
20,010.20
2,547.50
38,027.80
39,259.40
19,197.30
Total Equity
20,010.20
2,547.50
38,027.80
39,259.40
19,197.30
Liabilities & Shareholders' Equity
12,265.80
13,825.90
46,848.10
50,177.70
66,622.90

About Poxel

View Profile
Address
259/261, avenue Jean Jaurès
Lyon Rhone-Alpes 69007
France
Employees -
Website http://www.poxel.com
Updated 07/08/2019
Poxel SA is a pharmaceutical company, which engages in development of molecules for the potential treatment of type 2 diabetes. Its products include Imeglimin-US/EU, Imeglimin-Japan/Asia, and PXL770. The company was founded by Sébastien Bolze, Sophie Hallakou-Bozec, Pascale Fouqueray-Grellier, Pascale Malgouyres and Thomas Kuhn on March 6, 2009 and is headquartered in Lyon, France.